KBC Group’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $37K | Hold |
3,369
| – | – | ﹤0.01% | 1749 |
|
|
2025
Q4 | $44K | Hold |
3,369
| – | – | ﹤0.01% | 1670 |
|
|
2025
Q3 | $44K | Hold |
3,369
| – | – | ﹤0.01% | 1677 |
|
|
2025
Q2 | $60K | Sell |
3,369
-1,823
| -35% | -$31.8K | ﹤0.01% | 1512 |
|
|
2025
Q1 | $93K | Buy |
5,192
+101
| +2% | +$2.29K | ﹤0.01% | 1521 |
|
|
2024
Q4 | $152K | Buy |
5,091
+2,008
| +65% | +$42.5K | ﹤0.01% | 1299 |
|
|
2024
Q3 | $48K | Hold |
3,083
| – | – | ﹤0.01% | 1729 |
|
|
2024
Q2 | $53K | Hold |
3,083
| – | – | ﹤0.01% | 1582 |
|
|
2024
Q1 | $48K | Hold |
3,083
| – | – | ﹤0.01% | 1579 |
|
|
2023
Q4 | $46K | Buy |
3,083
+182
| +6% | +$2.44K | ﹤0.01% | 1587 |
|
|
2023
Q3 | $47K | Sell |
2,901
-7,857
| -73% | -$227K | ﹤0.01% | 1497 |
|
|
2023
Q2 | $446K | Sell |
10,758
-34,362
| -76% | -$2.13M | ﹤0.01% | 771 |
|
|
2023
Q1 | $2.71M | Buy |
45,120
+38,063
| +539% | +$3.04M | 0.01% | 603 |
|
|
2022
Q4 | $517K | Buy |
7,057
+383
| +6% | +$28.8K | ﹤0.01% | 758 |
|
|
2022
Q3 | $507K | Sell |
6,674
-32
| -0.5% | -$2.5K | ﹤0.01% | 759 |
|
|
2022
Q2 | $466K | Sell |
6,706
-1,983
| -23% | -$149K | ﹤0.01% | 773 |
|
|
2022
Q1 | $720K | Hold |
8,689
| – | – | ﹤0.01% | 741 |
|
|
2021
Q4 | $652K | Buy |
8,689
+1,720
| +25% | +$173K | ﹤0.01% | 800 |
|
|
2021
Q3 | $810K | Sell |
6,969
-6,969
| -50% | -$1.05M | ﹤0.01% | 786 |
|
|
2021
Q2 | $3.09M | Hold |
13,938
| – | – | 0.01% | 711 |
|
|
2021
Q1 | $1.84M | Hold |
13,938
| – | – | ﹤0.01% | 761 |
|
|
2020
Q4 | $13.3M | Buy |
13,938
+12,390
| +800% | +$1.7M | 0.01% | 724 |
|
|
2020
Q3 | $172K | Hold |
1,548
| – | – | ﹤0.01% | 1134 |
|
|
2020
Q2 | $92K | Sell |
1,548
-106
| -6% | -$6.97K | ﹤0.01% | 1225 |
|
|
2020
Q1 | $111K | Hold |
1,654
| – | – | ﹤0.01% | 1127 |
|
|
2019
Q4 | $139K | Buy |
1,654
+1,214
| +276% | +$98K | ﹤0.01% | 1326 |
|
|
2019
Q3 | $33K | Sell |
440
-4,334
| -91% | -$347K | ﹤0.01% | 1412 |
|
|
2019
Q2 | $302K | Hold |
4,774
| – | – | ﹤0.01% | 1166 |
|
|
2019
Q1 | $230K | Hold |
4,774
| – | – | ﹤0.01% | 1221 |
|
|
2018
Q4 | $160K | Hold |
4,774
| – | – | ﹤0.01% | 1152 |
|
|
2018
Q3 | $259K | Hold |
4,774
| – | – | ﹤0.01% | 1233 |
|
|
2018
Q2 | $149K | Sell |
4,774
-1,170
| -20% | -$32.5K | ﹤0.01% | 1171 |
|
|
2018
Q1 | $130K | Buy |
5,944
+1,220
| +26% | +$26.2K | ﹤0.01% | 1166 |
|
|
2017
Q4 | $95K | Buy |
+4,724
| New | +$91K | ﹤0.01% | 1183 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
KBC Group's NVCR Position: Q1 2026 in Review
KBC Group held its NovoCure (NVCR) position steady in Q1 2026 at 3,369 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.
KBC Group first reported a position in NVCR in Q4 2017 and has held it in 34 quarters since. The position peaked at $13.3M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- KBC Group held 3,369 shares of NovoCure worth $37K as of Q1 2026.
- KBC Group left its NovoCure share count unchanged in Q1 2026.
- NovoCure made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1749 holding.
- KBC Group first reported a position in NovoCure in Q4 2017 and has held it in 34 quarters since.
- KBC Group's NovoCure position peaked at $13.3M in Q4 2020.
- 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.